GOSS

Gossamer Bio Inc. (GOSS) | Rumor.io

Gossamer Bio

GOSS

Attention (50-day avg)0.01%

Attention rank (50-day avg)#639

Bullish sentiment (50-day avg)79%

Price to earnings ratio-0.19

Market capitalization70.5M

Earnings per share-52.7

Dividend yield (TTM)—

Revenue (annual)48.5M

Net income (annual)-170.4M

Social

What share of all stock conversation is about GOSS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Sep 24

Gossamer Bio's seralutinib has been submitted to the FDA for approval, with a potential PDUFA date in Q3.
The Phase 3 trial results showed a 13.3-meter improvement in 6-minute walk distance versus placebo, but fell short of the prespecified p-value threshold.
Analysts are revising their price targets upwards, with some predicting a potential stock price of $3000 per share if the company achieves a market capitalization similar to Insmed.

Generated by AI

Sentiment

Of the messages about GOSS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	75% -17.59	71.63% -10.46	78.45% -13.03
Bearish	0% -100	25% +17.59	28.37% +10.46	21.55% +13.03

Bullish· Aug 27

Gossamer Bio has a strong potential for FDA approval, with a $250,000,000 investment on the line, and the company's management is financially aligned with getting the drug approved.
The company has a buy rating from analyst Patrick Trucchio, who has a 64.6% success rate and an average return of 42.3% over the past year.
Institutional interest is notable, with D.E. Shaw-affiliated entities holding an 8.3% beneficial stake in GOSS, and insider compensation is tied to FDA approval, with the Chief Commercial Officer granted options covering about 5.8 million shares.

Bearish· Aug 26

The asset's price has plummeted 82% after a news article was shared on Stocktwits, sparking concerns about the company's performance.
Sellers are being encouraged to "stay away" from the asset, with one user claiming it will make them "scared", while another warns that the "feeling" will get halted "any time".
The asset's price is predicted to drop further, with some users calling for it to reach as low as $0.16, while others claim it is "over" and will continue to fall, with one user joking about the "algos doing the job".

Generated by AI

Topics

Of the messages about GOSS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	97.17%	53.19%
Technical Analysis	0%	0%	0%	9.97%
Analysts	0%	0%	2.83%	21.46%
Earnings	0%	0%	0%	0.95%
Controversies	0%	0%	0%	0.56%
Macro	0%	0%	0%	13.87%

Analysts· Dec 7

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on immunology, inflammation, and oncology therapeutics.
Analysts have lowered their target prices for GOSS, with Goldman Sachs cutting its target to $10, SVB Leerink to $10, and Bank of America to $7.
Despite the target price cuts, analysts maintain a "buy" rating for GOSS, citing a strong cash balance and potential for significant upside, with some estimates suggesting up to 1600% growth potential.

Announcements· Aug 21

Gossamer Bio, Inc. (GOSS) has announced a structured private placement of up to $250 million, including $150 million of committed capital, to fund the development of seralutinib through potential FDA approval.
The initial closing of $25 million is funded upfront, while an additional $125 million is contingent upon FDA acceptance of the new drug application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) in 2026.
The financing structure aligns capital availability with key regulatory milestones, with the potential for an additional $100 million in additional gross proceeds if the warrants are exercised following FDA approval.

Generated by AI

Community

Of the messages about GOSS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	67.25%	65.01%	40.52%
Newcomers	33.33%	32.75%	34.99%	59.48%

Regulars· Sep 24

The FDA will determine whether to accept the NDA for filing following its initial review of the application, which the Company anticipates could occur later this year.
The stock price is expected to be around $18.65 upon acceptance of the NDA, $37.30 per share upon PDUFA, and $74.63 per share upon approval, based on 13.4 million shares to account for dilution.
The company's market capitalization could potentially reach $1 billion upon approval, making the stock price around $74.63 per share, and the current market capitalization is considered low compared to the market cap of Insmed.

Newcomers· Sep 11

Gossamer Bio, Inc. ($GOSS) is effecting a 1-for-80 reverse stock split, reducing the tradeable float to approximately 3.0M – 6.0M shares.
New shareholders are questioning the math behind the split, with some wondering what price $GOSS may open at after the split.
The reverse split has resulted in a significant decrease in the number of shares, with some users speculating that this may lead to a decrease in the stock's price.

Generated by AI

News

Gossamer Bio Files New Drug Application for Seralutinib

Gossamer Bio (GOSS) said late Wednesday it has submitted a new drug application to the US Food and D

6d agoYahoo Finance

Gossamer Bio stock rises on FDA filing for PAH drug

6d agoInvesting.com

Gossamer Bio submits NDA for seralutinib in PAH treatment

6d agoInvesting.com

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme

6d agoYahoo Finance

Gossamer Bio Adds Veteran Investor to Board of Directors

Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

SAN DIEGO, September 16, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.

13d agoYahoo Finance

Also Discussed

Investors talking about GOSS also mention

#	Name	Attention
1	Adagene Inc. ADRADAG	0%0
2	IDEAYA Biosciences Inc.IDYA	0%-0.01
3	PolyPid Ltd.PYPD	0%new
4	Grace Therapeutics, Inc.GRCE	0%new
5	Crinetics Pharmaceuticals IncCRNX	0%0
6	LiveWire Group, Inc.LVWR	0%new
7	Compass Therapeutics, Inc.CMPX	0%new
8	Elicio Therapeutics Inc.ELTX	0%0
9	I-Mab Sponsored ADRIMAB	0%0
10	AMAM - Ambrx Biopharma Inc.	——

Gossamer Bio Inc.

Healthcare
Biotechnology

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary and inflammatory diseases. Its lead product candidate, seralutinib, is being studied for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also works on other drug candidates for immune-driven and respiratory conditions, using an approach centered on discovering and advancing targeted treatments. Gossamer Bio Inc. plays a specialized role in the healthcare market by addressing serious diseases with significant unmet medical need through its research, development, and clinical trial programs. The company is headquartered in San Diego, California.

Website

Location

3115 Merryfield Row

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about GOSS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Sep 24

Gossamer Bio's seralutinib has been submitted to the FDA for approval, with a potential PDUFA date in Q3.
The Phase 3 trial results showed a 13.3-meter improvement in 6-minute walk distance versus placebo, but fell short of the prespecified p-value threshold.
Analysts are revising their price targets upwards, with some predicting a potential stock price of $3000 per share if the company achieves a market capitalization similar to Insmed.

Generated by AI

Sentiment

Of the messages about GOSS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	75% -17.59	71.63% -10.46	78.45% -13.03
Bearish	0% -100	25% +17.59	28.37% +10.46	21.55% +13.03

Bullish· Aug 27

Gossamer Bio has a strong potential for FDA approval, with a $250,000,000 investment on the line, and the company's management is financially aligned with getting the drug approved.
The company has a buy rating from analyst Patrick Trucchio, who has a 64.6% success rate and an average return of 42.3% over the past year.
Institutional interest is notable, with D.E. Shaw-affiliated entities holding an 8.3% beneficial stake in GOSS, and insider compensation is tied to FDA approval, with the Chief Commercial Officer granted options covering about 5.8 million shares.

Bearish· Aug 26

The asset's price has plummeted 82% after a news article was shared on Stocktwits, sparking concerns about the company's performance.
Sellers are being encouraged to "stay away" from the asset, with one user claiming it will make them "scared", while another warns that the "feeling" will get halted "any time".
The asset's price is predicted to drop further, with some users calling for it to reach as low as $0.16, while others claim it is "over" and will continue to fall, with one user joking about the "algos doing the job".

Generated by AI

Topics

Of the messages about GOSS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	97.17%	53.19%
Technical Analysis	0%	0%	0%	9.97%
Analysts	0%	0%	2.83%	21.46%
Earnings	0%	0%	0%	0.95%
Controversies	0%	0%	0%	0.56%
Macro	0%	0%	0%	13.87%

Analysts· Dec 7

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on immunology, inflammation, and oncology therapeutics.
Analysts have lowered their target prices for GOSS, with Goldman Sachs cutting its target to $10, SVB Leerink to $10, and Bank of America to $7.
Despite the target price cuts, analysts maintain a "buy" rating for GOSS, citing a strong cash balance and potential for significant upside, with some estimates suggesting up to 1600% growth potential.

Announcements· Aug 21

Gossamer Bio, Inc. (GOSS) has announced a structured private placement of up to $250 million, including $150 million of committed capital, to fund the development of seralutinib through potential FDA approval.
The initial closing of $25 million is funded upfront, while an additional $125 million is contingent upon FDA acceptance of the new drug application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) in 2026.
The financing structure aligns capital availability with key regulatory milestones, with the potential for an additional $100 million in additional gross proceeds if the warrants are exercised following FDA approval.

Generated by AI

Community

Of the messages about GOSS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	67.25%	65.01%	40.52%
Newcomers	33.33%	32.75%	34.99%	59.48%

Regulars· Sep 24

The FDA will determine whether to accept the NDA for filing following its initial review of the application, which the Company anticipates could occur later this year.
The stock price is expected to be around $18.65 upon acceptance of the NDA, $37.30 per share upon PDUFA, and $74.63 per share upon approval, based on 13.4 million shares to account for dilution.
The company's market capitalization could potentially reach $1 billion upon approval, making the stock price around $74.63 per share, and the current market capitalization is considered low compared to the market cap of Insmed.

Newcomers· Sep 11

Gossamer Bio, Inc. ($GOSS) is effecting a 1-for-80 reverse stock split, reducing the tradeable float to approximately 3.0M – 6.0M shares.
New shareholders are questioning the math behind the split, with some wondering what price $GOSS may open at after the split.
The reverse split has resulted in a significant decrease in the number of shares, with some users speculating that this may lead to a decrease in the stock's price.

Generated by AI

Gossamer Bio

Social

Sep 24

Bullish· Aug 27

Bearish· Aug 26

Analysts· Dec 7

Announcements· Aug 21

Regulars· Sep 24

Newcomers· Sep 11

Gossamer Bio Files New Drug Application for Seralutinib

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio submits NDA for seralutinib in PAH treatment

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Adds Veteran Investor to Board of Directors

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Also Discussed

Gossamer Bio Inc.

Company Information

Location

Gossamer Bio Files New Drug Application for Seralutinib

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio submits NDA for seralutinib in PAH treatment

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Adds Veteran Investor to Board of Directors

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Also Discussed

Social

Sep 24

Bullish· Aug 27

Bearish· Aug 26

Analysts· Dec 7

Announcements· Aug 21

Regulars· Sep 24

Newcomers· Sep 11